Beta-defensin 131B

Also known as: Defensin, beta 131, DEFB131B, A0A096LNP1

Beta-defensin 131B (DEFB131B, UniProt A0A096LNP1) is an experimental antimicrobial peptide belonging to the beta-defensin family. Its proposed mechanism of action involves direct antibacterial activity, likely through disruption of bacterial cell membranes via electrostatic interactions with negatively charged microbial surfaces, leading to pore formation and cell lysis. This mechanism is characteristic of defensins, which are cationic, cysteine-rich peptides that play a role in innate immune defense against pathogens. Currently, there are no published peer-reviewed studies indexed in PubMed specifically investigating beta-defensin 131B. Research status remains experimental, with no validated functional data or in vivo models available. The lack of primary literature limits understanding of its spectrum of activity, potency, or potential synergy with other immune factors. Further studies are required to confirm its antibacterial efficacy and elucidate its biological role. Given the absence of clinical data, beta-defensin 131B has no established therapeutic relevance at this time. Its potential applications in antimicrobial therapy remain speculative until rigorous preclinical and clinical evaluations are conducted. For research purposes only — not medical advice.

Key data

Mechanism of action

Has antibacterial activity

Frequently asked questions

Related peptides